GENE ONLINE|News &
Patient Compliance Reaches 97% in Two Study Groups
Patient compliance reached statistically significant levels, with rates as high as 97% in both study groups. The study tracked patient adherence to treatment plans across two separate arms. Researchers observed that both groups demonstrated remarkably similar and statistically significant compliance rates. Specifically, the data indicated that patients in both arms of the study followed their prescribed regimens up to 97% of the time.
Newsflash | Powered by GeneOnline AI
Date: April 24, 2025
Related posts:
NIH Reverses Contract Cuts After Surpassing Spending Reduction Goals
Symptom Relief Reported in Diet Study, But No Single Food Identified as Key Factor
Could investigational drug become first-in-class bronchiectasis therapy?
BlueRock Therapeutics announces publication in Nature of 18-month data from Phase 1 clinical trial for bemdaneprocel, an investigational cell therapy for Parkinson’s disease
LATEST
VintaBio Showcases High-Yield VintaProcess Platform for Gene Therapy Vector Production at ASGCT 2025
2025-05-15
Boehringer Ingelheim and Tempus AI Partner in Multi-Year Collaboration to Enhance Oncology Drug Development
2025-05-15
Study: Aligning U.S. Drug Prices with Europe Could Reduce American Life Expectancy by Six Months
2025-05-15
